Drug intelligence / Profile preview

ConS UFO

Development stage: Phase 1
Modality: Recombinant Proteins and Enzymes, Therapeutic Vaccines → Vaccines & Immunotherapeutics

Overview

ConS UFO is a rationally-designed model immunogen based on the HIV-1 envelope (Env) glycoprotein gp140 trimer. It incorporates a short flexible amino-acid linker to tether the gp120 and gp41 subunits, preventing their dissociation and stabilizing the Env trimer in a native-like conformation. This design aims to induce broadly neutralizing antibodies (bNAbs) against HIV-1 by focusing B cell responses towards conserved neutralization epitopes. It is being investigated in experimental medicine studies to understand immune responses and inform future vaccine design.

Targets

gp41 (Human immunodeficiency virus type 1 glycoprotein 41)

Beyond the preview

Go deeper on ConS UFO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ConS UFO.

Explore the full profile